Why Centessa Pharmaceuticals is Drawing Investor Attention

Centessa Pharmaceuticals (CNTA) has been drawing interest after posting a 1-day share price move of around 0.1%, alongside strong multi period returns. This is prompting fresh questions about how the stock’s risk and reward now stack up.

While the latest 1-day share price return was slightly negative, recent interest in Centessa has been shaped more by its powerful longer term move. The share price has posted a 90-day return above 50% and a 1-year total shareholder return above 200%, indicating momentum that investors are watching closely relative to its current US$39.85 trading level.

If you are looking beyond Centessa for other potential growth stories in healthcare, this could be a useful moment to scan opportunities in companies using artificial intelligence in medicine through the 39 healthcare AI stocks

With Centessa’s strong multi period returns, a price near US$39.85 and an analyst target around US$44.57, the key question now is whether the stock is still undervalued or if markets are already pricing in future growth.

Preferred Price to Book Ratio of 12.7x: Is it justified?

Centessa currently trades on a P/B of 12.7x, which sits against a share price of $39.85 and an analyst price target around $44.57.

The P/B ratio compares the company’s market value to its book value, so a higher figure usually implies investors are paying a premium over the current net assets. For early stage biotech businesses, this often reflects expectations around future drug candidates rather than existing revenue. Centessa currently reports less than $1m of revenue and a loss of $250.638m.

Relative to the wider US Biotechs industry, where the average P/B sits at 2.4x, Centessa’s 12.7x multiple is substantially higher. This suggests the market is assigning a much richer valuation than the sector as a whole. Compared with a peer group average P/B of 21.7x, however, the company screens as lower on this metric. This points to some investors seeing it as less highly priced than certain closer peers even with that premium to the broader industry.

Result: Price-to-book of 12.7x (ABOUT RIGHT)

However, the story can change quickly if clinical trial outcomes underwhelm or if the company’s ongoing loss of US$250.638m makes future funding more difficult or more expensive.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Discounted Cash Flow Signals Deep Underpricing

While the 12.7x P/B ratio makes Centessa look expensive next to the broader US Biotechs sector, the SWS DCF model points in a very different direction. With the stock at $39.85 and an estimated future cash flow value of $158, it screens as heavily undervalued. Which signal should matter more to you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Centessa Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a mix of strong recent returns and clear risks around losses and funding, it makes sense to review the data for yourself and decide where you stand. If you want a concise summary of both sides of the story, take a closer look at the 2 key rewards and 5 important warning signs

Looking for more investment ideas?

If Centessa has sharpened your focus, do not stop here. Broaden your watchlist now so you are not chasing the next opportunity after it moves.

• Target companies that combine quality with a potential discount by scanning 47 high quality undervalued stocks before prices move away from you.
• Strengthen your income stream by reviewing stocks in the 10 dividend fortresses and see which yields might fit your goals.
• Prioritise resilience by tracking companies highlighted in the 63 resilient stocks with low risk scores so you can focus on steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.